BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The National Drug Abuse Treatment Clinical Trials Network - Northeast Node - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.ctnnortheastnode.org
X-WR-CALDESC:Events for The National Drug Abuse Treatment Clinical Trials Network - Northeast Node
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260501T120000
DTEND;TZID=America/New_York:20260501T133000
DTSTAMP:20260506T072802
CREATED:20260320T152746Z
LAST-MODIFIED:20260320T152746Z
UID:3453-1777636800-1777642200@www.ctnnortheastnode.org
SUMMARY:Trapped in Cyberspace: Understanding Internet Addiction
DESCRIPTION:New England Addiction Technology Transfer Webinar \nLearn about the link between problem gambling and death by suicide\, including key risk factors like financial strain\, relationship challenges\, and co-occurring alcohol use. Gain insights from emerging data to better inform prevention\, improve data collection\, and strengthen clinical support. \nClick to Register
URL:https://www.ctnnortheastnode.org/event/trapped-in-cyberspace-understanding-internet-addiction/
CATEGORIES:Other Related
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260505T130000
DTEND;TZID=America/New_York:20260505T140000
DTSTAMP:20260506T072802
CREATED:20260209T173249Z
LAST-MODIFIED:20260209T181043Z
UID:3441-1777986000-1777989600@www.ctnnortheastnode.org
SUMMARY:A Primer on the Revised ASAM Criteria for Pregnant and Parenting Adolescents with Substance Use Disorders
DESCRIPTION:REGISTER NOW \n  \nABOUT OUR TRAINER: \nDr. Lauren Micalizzi is an Assistant Professor in the Department of \nBehavioral and Social Sciences at Brown University’s School of Public \nHealth\, where she bridges developmental and addiction science. Her \nresearch\, stemming from a PhD in Developmental Science from Boston \nUniversity and a postdoctoral fellowship at Brown’s Center for Alcohol \nand Addiction Studies\, focuses on the parent-child dyad during the \nperinatal period and adolescence. She investigates how parental \nsubstance use and mental health affect parenting\, relationship quality\, \nand child development\, with a central focus on the etiology\, treatment\, \nand long-term implications of perinatal substance use\, while also exploring \nintergenerational risk and protective factors. \n  \nDESCRIPTION: \nThis training explores the major revisions introduced in the ASAM Criteria 4th \nEdition\, focusing specifically on the unique developmental and clinical needs of \npregnant and parenting adolescents. Participants will identify key strategies for \ntreating substance use in this population while evaluating the system-level \nimplications of these updated standards on care delivery. By the end of the session\, \nattendees will have a practical framework for implementing these changes to \nimprove outcomes for young families within the shifting landscape of behavioral \nhealth. \n  \nREGISTER NOW
URL:https://www.ctnnortheastnode.org/event/a-primer-on-the-revised-asam-criteria-for-pregnant-and-parenting-adolescents-with-substance-use-disorders/
CATEGORIES:Other Related
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260506T170000
DTEND;TZID=America/New_York:20260506T180000
DTSTAMP:20260506T072802
CREATED:20260504T202237Z
LAST-MODIFIED:20260504T202237Z
UID:3464-1778086800-1778090400@www.ctnnortheastnode.org
SUMMARY:Update on the diversification of kratom-derived products: 7-hydroxymitragynine\, pseudoindoxyl\, and beyond
DESCRIPTION:ORN Spring 2026 Hot Topics in Addiction Medicine \nDescription: This talk will provide a background on traditional kratom and an overview of the recent proliferation of novel\, kratom-derived products. Industry marketing\, confused media coverage\, and dynamic government policy will be described\, as all influence public health responses. What is known about the harm-reduction aspects of these kratom compounds will be considered. Next steps for developing a better epidemiological understanding will be identified along with the roles clinicians play. The pharmacology of kratom\, 7-hydroxymitragynine (7-OH)\, and mitragynine pseudoindoxyl will be explained in a manner geared at helping clinicians understand how pharmacology influences addiction potential. Patient-level factors that may influence substance use disorder or adverse event trajectories will be articulated. Use motivations will be discussed alongside risks. Case reports will be used to highlight the complexity of assessing\, diagnosing\, and treating patients consuming new kratom-derived products. Ample time for attendee Q&A will be reserved to facilitate learning and discussion. \nLearning Objectives: At the conclusion of this webinar\, attendees will be able to: \n\nUpon completion\, describe the basic pharmacology\, toxicology\, effects\, risks\, and benefits associated with kratom and kratom-derived products containing 7-hydroxymitragynine (“7-OH”)\, mitragynine pseudoindoxyl (“pseudo”)\, along with related compounds such as kava\, and MGM-15.\nUpon completion\, participants will be able to engage in improved identification of kratom product use\, conduct highly specified clinical assessments\, and better diagnosis and manage SUDs related to kratom-derived products in a data-informed and patient-centered manner.\nUpon completion\, participants will be able to define the dynamic state and federal policy and regulatory landscape surrounding kratom and kratom-derived products.\n\nKirsten Smith\, Ph.D\, L.M.S.W \nREGISTER
URL:https://www.ctnnortheastnode.org/event/update-on-the-diversification-of-kratom-derived-products-7-hydroxymitragynine-pseudoindoxyl-and-beyond/
CATEGORIES:Other Related
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260512T120000
DTEND;TZID=America/New_York:20260512T133000
DTSTAMP:20260506T072802
CREATED:20260320T152435Z
LAST-MODIFIED:20260320T152435Z
UID:3452-1778587200-1778592600@www.ctnnortheastnode.org
SUMMARY:Older Adults and Casino Gambling: Behaviors\, Motivations\, and Risk
DESCRIPTION:New England Addiction Technology Transfer Webinar \nLearn what motivates older adults to gamble and the factors that increase their risk for Gambling Disorder as this population evolves. Explore key implications for prevention and reducing gambling-related harm among older adults. \nClick to Register
URL:https://www.ctnnortheastnode.org/event/older-adults-and-casino-gambling-behaviors-motivations-and-risk/
CATEGORIES:Other Related
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260512T130000
DTEND;TZID=America/New_York:20260512T140000
DTSTAMP:20260506T072802
CREATED:20260209T174045Z
LAST-MODIFIED:20260209T174045Z
UID:3445-1778590800-1778594400@www.ctnnortheastnode.org
SUMMARY:A Practical Overview of Treating Cannabis Use in the Perinatal Period
DESCRIPTION:REGISTER NOW \nABOUT THE TRAINER: \nDr. Lindy Howe is a postdoctoral research fellow at the Center for Alcohol and \nAddiction Studies at Brown University. Lindy’s research interests center on \nsubstance use\, particularly examining the interplay between psychopathology\, \ndecision-making\, and situational factors of alcohol and cannabis use through \necological momentary assessment. Her emerging research interests also explore \nthe interaction of substance use with perinatal mental health\, specifically focusing \non the role providers play in shaping perceptions of cannabis use before\, during\, \nand after pregnancy\, the factors contributing to the return of substance use \npostpartum\, and the impact of cannabis and alcohol use on postpartum mental \nhealth outcomes. \n  \nDESCRIPTION: \nThis training provides an evidence-based framework for addressing cannabis use in \nperinatal populations\, focusing on key clinical considerations and the management of co- \noccurring mental health factors. Through the discussion of applied case examples\, \nparticipants will learn to navigate complications and implement practical interventions \nwithin pregnancy and postpartum treatment settings. \n  \nLEARNING OBJECTIVES: \nDescribe evidence-based interventions for addressing cannabis use during pregnancy \nand the postpartum period. \nIdentify key clinical considerations\, complications\, and co-occurring mental health \nfactors relevant to treating cannabis use in perinatal populations. \nApply a general framework for approaching cannabis use within perinatal treatment \nsettings (e.g.\, mental health and substance use care) through discussion of applied case \nexamples. \n  \nREGISTER NOW
URL:https://www.ctnnortheastnode.org/event/a-practical-overview-of-treating-cannabis-use-in-the-perinatal-period/
CATEGORIES:Other Related
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260513T170000
DTEND;TZID=America/New_York:20260513T180000
DTSTAMP:20260506T072802
CREATED:20260504T201144Z
LAST-MODIFIED:20260504T201144Z
UID:3462-1778691600-1778695200@www.ctnnortheastnode.org
SUMMARY:Medetomidine Impacts on Clinical Management and Systems of Care
DESCRIPTION:ORN Spring 2026 Hot Topics in Addiction Medicine\n\nDescription: \nMedetomidine\, a highly potent veterinary alpha-2 adrenergic agonist\, has recently emerged as a significant adulterant within the U.S. illicit opioid supply. This presentation entitled will review the introduction of medetomidine in the U.S. drug supply\, the pharmacology and clinical effects of medetomidine\, and the distinguishing features of medetomidine toxicity and withdrawal. We will outline emerging treatment strategies emphasizing early\, aggressive alpha-2 agonist therapy; nuanced antiemetic approaches; when and how to escalate to IV dexmedetomidine; and approaches to concurrent opioid withdrawal management. Participants will gain insight into diagnostic challenges\, observation and disposition considerations\, and strategies for system-level preparedness. \nLearning Objectives:\n\nDescribe the emergence of medetomidine as an illicit drug adulterant and its impact on overdose toxicity and withdrawal presentations.\nRecognize the clinical features of medetomidine toxicity and differentiate medetomidine withdrawal from withdrawal syndromes.\nApply evidence-informed strategies for early\, aggressive management of medetomidine withdrawal\, including the use of alpha-2 agonists and antiemetic therapies.\nIdentify system-level challenges posed by medetomidine and outline approaches to multidisciplinary coordination.\n\nMichael Lynch\, MD \nREGISTER
URL:https://www.ctnnortheastnode.org/event/medetomidine-impacts-on-clinical-management-and-systems-of-care/
CATEGORIES:Other Related
END:VEVENT
END:VCALENDAR